Tải xuống
Tóm tắt
ABSTRACT
Introduction: The global rise in aging population led to the increase of the number of elderly patients with lung cancer. Due to the impairment of the function of multiple organs, the work-up and treatment NSCLC for older patients become more difficult than adults. Because of lacking data about the characteristics of NSCLC in older patients, we conducted this study with the aims:
Objectives
- To describe clinical, subclinical features and treatment of NSCLC in elderly patients.
- To evaluate the ability of predicting chemotoxicity of CARG score.
- To evaluate the efficacy of chemotherapy by the Progression-Free Survival.
Patients & method: A retrospective study was conducted in a cohort of 26 patients older than 60, diagnosed with advanced NSCLC and treated by chemotherapy at least 3 cycles at Hue University Hospital from 1/7/2018 to 1/7/2019. Statistical analysis was performed in Microsoft Excel 2016 and R 3.6.0 program.
Results: The mean age of patients was 69.46±6.80 (range 60-82) with stage IIIb (15.38%) or IV (84.62%). Gemcitabine plus Carboplatin was the most common regimen (46.15%), followed by Vinorelbine (30.77%), Paclitaxel plus Carboplatin (19.23%) and Gemcitabine (3.85%). Chemotherapy-induced anemia was most frequent hematologic toxicity, up to grade 3. There was a significant difference in toxicity among the three toxicity risk groups (p=0.0019). The median time to progression was 5 months.
Conclusion: In elderly patients, the characteristics of our cohort was relatively identical to other studies in Vietnam. The median of PFS was 5 months in our sample. CARG score can be used to predict chemotoxicity before treating elderly patients.
Tài liệu tham khảo
Bray F., Ferlay J., Soerjomataram I., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide
for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68, 394–424,
Jemal A., Bray F., Center M.M., et al. (2011). Global cancer statistics. CA Cancer J Clin, 61(2), 69–90.
Brown J.S., Eraut D., Trask C., et al. (1996). Age and the treatment of lung cancer. Thorax, 51(6), 564–568.
Radzikowska E., Głaz P., and Roszkowski K. (2002). Lung cancer in women: age, smoking, histology, performance status, stage, initial
treatment and survival. Population-based study of 20 561 cases. Ann Oncol, 13(7), 1087–1093.
Trung N.Q., Le N.T.T., Hung T.D., et al. (2018). Phan tich dac diem phan tu benh nhan ung thu phoi khong te bao nho tai Benh vien Ung buou
Nghe An. Nghe An Oncology Hospital, 56–61.
Van Linh P. (2010). Nghien cuu ung dung dao Gamma trong dieu tri ung thu phoi tai Benh vien Truong Dai hoc Y Duoc - Dai hoc Hue. Hue
University Journal of Science, 107–120.
Santos F.N., de Castria T.B., Cruz M.R.S., et al. (2015). Chemotherapy for advanced nonsmall cell lung cancer in the elderly population. Cochrane Database Syst Rev, (10), CD010463.
Kim J. and Hurria A. (2013). Determining chemotherapy tolerance in older patients with cancer. J Natl Compr Canc Netw, 11(12), 1494–
Hurria A., Togawa K., Mohile S.G., et al. (2011). Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol, 29(25), 3457–3465.
Trotti A., Colevas A.D., Setser A., et al. (2003). CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer
treatment. Semin Radiat Oncol, 13(3), 176–181.
Schwartz L.H., Litière S., de Vries E., et al. (2016). RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer, 62, 132–137.
Nie X., Liu D., Li Q., et al. (2013). Predicting chemotherapy toxicity in older adults with lung cancer. J Geriatr Oncol, 4(4), 334–339.
Risteski M., Crvenkova S., Atanasov Z., et al. (2013). Epidemiological analysis of progressionfree survival (PFS) and overall survival (OS) in
non-small-cell lung cancer patients in Republic of Macedonia. Pril (Makedon Akad Nauk Umet Odd Med Nauki), 34(3), 49–61.
Sweeney C.J., Zhu J., and Sandler A.B. (2001). Outcome of patients with a performance status of 2 in eastern cooperative oncology group study E1594: a phase III trial in patients with metastatic nonsmall cell lung …. Journal of the ….
| Đã xuất bản | 24-01-2025 | |
| Toàn văn |
|
|
| Ngôn ngữ |
|
|
| Số tạp chí | Số 56 (2019) | |
| Phân mục | Nghiên cứu | |
| DOI | ||
| Từ khóa | Keywords: advanced non-small cell lung cancer, chemotoxicity |
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International .
Bản quyền (c) 2019 Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế